menu
    • menu
    [{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BofA Securities"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Privosegtor

    Menu

    Privosegtor

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Oculis

    Switzerland arrow
    German Wound Congress
    Not Confirmed

    Oculis

    Switzerland arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Privosegtor

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : BofA Securities

    Deal Size : $100.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

    Details : Oculis intends to use the net proceeds from the Offering to advance and accelerate its clinical development pipeline, which include Privosegtor (OCS-05) is being evaluated for acute optic neuritis.

    Product Name : OCS-05

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 13, 2025

    Lead Product(s) : Privosegtor

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : BofA Securities

    Deal Size : $100.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Oculis

    Switzerland arrow
    German Wound Congress
    Not Confirmed

    Oculis

    Switzerland arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Privosegtor

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Oculis’ OCS-05 Meets Key Endpoints in Phase 2 Acute Optic Neuritis Trial

    Details : OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator. It is being evaluated for the treatment of patients with acute optic neuritis.

    Product Name : OCS-05

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 06, 2025

    Lead Product(s) : Privosegtor

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Oculis

    Switzerland arrow
    German Wound Congress
    Not Confirmed

    Oculis

    Switzerland arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Privosegtor

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Oculis Completes Enrollment in Phase 2 ACUITY Trial with OCS-05 for Acute Optic Neuritis

    Details : OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator. It is being evaluated for the treatment of patients with acute optic neuritis.

    Product Name : OCS-05

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 05, 2024

    Lead Product(s) : Privosegtor

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth